Protein 'Leak' Proves Reliable Stand-in for Kidney Failure in Clinical Trials

Testing new treatments for Immunoglobulin A (IgA) nephropathy, a rare condition that carries a high risk of kidney failure, presents a significant challenge. Clinical trials that wait for kidney failure to occur as their primary endpoint are often unfeasible due to the large number of participants and long follow-up periods required.

To overcome this, researchers use surrogate endpoints—early indicators that predict long-term outcomes. For IgA nephropathy, the key surrogate is proteinuria, the presence of excess protein in the urine. An updated meta-analysis, incorporating new patient-level data, has reinforced the validity of this approach.

The research found a strong correlation (with an R² of 0.80) between a treatment's ability to reduce proteinuria within nine months and its long-term success in preventing serious outcomes. This finding provides further confidence for regulators and scientists that focusing on proteinuria in randomised controlled trials is a reliable way to gauge a new therapy's effectiveness.